Achieving Remission in Chronic Lymphocytic Leukemia With CD4+ CAR T-Cells: Jan Joseph Melenhorst, PhD

Video

The translational immunologist and research professor at Perelman School of Medicine, University of Pennsylvania, discussed persistence of CD4+ CAR T-cells in CLL.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Jan Joseph Melenhorst, BSc, MS, PhD, translational immunologist, research professor of pathology and laboratory medicine, Department of Pathology and Laboratory Medicine Graduate Group Affiliations, Perelman School of Medicine, University of Pennsylvania, to learn more about the persistence of CD4+ CAR T-cells in chronic lymphocytic leukemia (CLL) and the ability of these cells to induce remissions in patients.

CART-19 is , a CD19-redirected CAR T-cell therapy that was evaluated in a phase 1 study. Two evaluable patients with CLL were in remission or being cured of their disease with the treatment, Melenhorst said. Moreover, the study applied novel technologies to understand every individual cell at a detailed level, Melenhorst added.

Knowledge of the cells’ health status was obtained, revealing whether the cells were exhausted, activated, or proliferating killer cells, Melenhorst continues. Moreover, the findings showed that the CD4+ T cells exhibited features of memory, proliferation, and cytolytic activities, which seem to be compartmentalized in the population, Melenhorst concluded.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.